Technological advancements in antibody-based therapeutics for treatment of diseases

Monoclonal antibodies (mAbs) represent a major class of therapeutics with widespread clinical applications in oncology, immunology, hematology, neurology and infectious disease. Since the introduction of hybridoma technology in 1975, the field has been advanced by a succession of innovations including chimeric and humanized antibody engineering, phage display, transgenic mouse platforms and high-throughput single B cell isolation. These technological developments have enhanced the specificity, potency and safety of mAbs, resulting in 144 FDA-approved antibody drugs on the market and 1,516 worldwide candidates in clinical development as of August 2025. Engineering breakthroughs have led to new modalities of antibody-based therapeutics, such as antibody-drug conjugates (ADCs), bispecific antibodies (bsAbs), and chimeric antigen receptor T (CAR-T) cell therapies. Each of these modalities has therapeutic utility across multiple disease domains. Recent advances in delivery strategies, notably mRNA-lipid nanoparticles (LNPs) and antibody-directed in vivo CAR-T cell reprogramming, can enable precision therapies while reducing off-target effects and manufacturing complexity. The integration of artificial intelligence (AI) and machine learning (ML), next-generation sequencing (NGS), and structural modeling tools has further accelerated antibody discovery, affinity maturation and immunogenicity prediction, allowing for more efficient and rational antibody design. The advances in antibody technology are reflected in the rapid market growth of antibody-based therapeutics, which had global sales exceeding USD 267 billion in 2024. This review provides a comprehensive update on recent developments in antibody discovery platforms, therapeutic formats and market trends, highlighting emerging strategies that are reshaping the landscape of antibody-based medicine. Furthermore, we discuss clinical translation, regulatory landscapes, and the integration of engineering, biology and informatics. Together, these aspects shape a dynamic and multidisciplinary future for the therapeutic antibody field, which is poised to address unmet clinical needs and global healthcare priorities.

• Publication year

  2025

• Venue

  Journal of Biomedical Sciences

• Publication date

  2025-11-12

• Fields of study

  Medicine, Engineering

• Identifiers
  DOI 10.1186/s12929-025-01190-2PMID 41219972PMCID 12606834
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prodrug-based bispecific antibodies for cancer therapy: advances and future directions

  2025cited by this paper
• Engineering sonogenetic EchoBack-CAR T cells.

  2025cited by this paper
• Trends and challenges in bispecific antibody production.

  2025cited by this paper
• CAR T cells based on fully human T cell receptor-mimetic antibodies exhibit potent antitumor activity in vivo.

  2025cited by this paper
• Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review

  2025cited by this paper
• Cell-based glycoengineering for production of homogeneous and specific glycoform-enriched antibodies with improved effector functions

  2025cited by this paper
• Nanoparticle delivery of a prodrug-activating bacterial enzyme leads to anti-tumor responses

  2025cited by this paper
• Apolipoprotein Fusion Enables Spontaneous Functionalization of mRNA Lipid Nanoparticles with Antibody for Targeted Cancer Therapy

  2025cited by this paper
• Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools

  2025cited by this paper
• In vivo CAR T cell generation to treat cancer and autoimmune disease.

  2025cited by this paper
• FDA Approval Summary: Datopotamab deruxtecan-dlnk for treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer.

  2025cited by this paper
• Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial

  2025cited by this paper
• Top companies and drugs by sales in 2024

  2025cited by this paper
• Antibody-oligonucleotide conjugates in cancer therapy: Potential and Promise.

  2025cited by this paper
• LNP-RNA-mediated antigen presentation leverages SARS-CoV-2-specific immunity for cancer treatment

  2025cited by this paper
• Atomically accurate de novo design of antibodies with RFdiffusion

  2025cited by this paper
• Targeted mRNA delivery with bispecific antibodies that tether LNPs to cell surface markers

  2024cited by this paper
• In vivo CAR T cells move into clinical trials

  2024cited by this paper
• Lipid-Encapsulated mRNAs Encoding Complex Fusion Proteins Potentiate Antitumor Immune Responses

  2024cited by this paper
• Monoclonal Antibody Generation Using Single B Cell Screening for Treating Infectious Diseases

  2024cited by this paper
• Advancing Antibody Engineering through Synthetic Evolution and Machine Learning.

  2024cited by this paper
• Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy

  2024cited by this paper
• A new era of antibody discovery: an in-depth review of AI-driven approaches.

  2024cited by this paper
• Assessing antibody and nanobody nativeness for hit selection and humanization with AbNatiV

  2024cited by this paper
• rAbDesFlow: a novel workflow for computational recombinant antibody design for healthcare engineering.

  2024cited by this paper
• Dual blockade immunotherapy targeting PD-1/PD-L1 and CTLA-4 in lung cancer

  2024cited by this paper
• In vivo human T cell engineering with enveloped delivery vehicles

  2024cited by this paper
• Design and engineering of bispecific antibodies: insights and practical considerations

  2024cited by this paper
• Current landscape of mRNA technologies and delivery systems for new modality therapeutics

  2024cited by this paper
• Bispecific antibodies: advancing precision oncology.

  2024cited by this paper
• Generation of a Naïve Human scFv Phage Display Library and Panning Selection.

  2024cited by this paper
• Accurate structure prediction of biomolecular interactions with AlphaFold 3

  2024cited by this paper
• Radiotherapy activates picolinium prodrugs in tumours

  2024cited by this paper
• Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years

  2024cited by this paper
• CAR T Cells and T-Cell Therapies for Cancer: A Translational Science Review.

  2024cited by this paper
• The Journey of Antibody-Drug Conjugates: Lessons Learned from 40 Years of Development.

  2024cited by this paper
• BiSpec Pairwise AI: guiding the selection of bispecific antibody target combinations with pairwise learning and GPT augmentation

  2024cited by this paper
• Preclinical efficacy and pharmacokinetics of an RNA-encoded T cell–engaging bispecific antibody targeting human claudin 6

  2024cited by this paper
• The antibody–drug conjugate landscape

  2024cited by this paper
• Broadly inhibitory antibodies to severe malaria virulence proteins

  2024cited by this paper
• Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies

  2024cited by this paper
• Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria.

  2024cited by this paper
• Atomically accurate de novo design of antibodies with RFdiffusion

  2024cited by this paper
• The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention

  2024cited by this paper
• Updated resources for exploring experimentally-determined PDB structures and Computed Structure Models at the RCSB Protein Data Bank

  2024cited by this paper
• The present and future of bispecific antibodies for cancer therapy

  2024cited by this paper
• Top companies and drugs by sales in 2023

  2024cited by this paper
• Improved deep learning prediction of antigen–antibody interactions

  2024cited by this paper
• Potent human antibodies against SpA5 identified by high-throughput single-cell sequencing of phase I clinical volunteers’ B cells

  2024cited by this paper
• AbImmPred: An immunogenicity prediction method for therapeutic antibodies using AntiBERTy-based sequence features

  2024cited by this paper
• Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial final results

  2024cited by this paper
• Dupilumab: Mechanism of action, clinical, and translational science

  2024cited by this paper
• Monoclonal antibodies: From magic bullet to precision weapon

  2024cited by this paper
• Transient CAR T cells with specificity to oncofetal glycosaminoglycans in solid tumors

  2024cited by this paper
• Advancements and challenges in developing in vivo CAR T cell therapies for cancer treatment

  2024cited by this paper
• Overcoming Limitations and Advancing the Therapeutic Potential of Antibody-Oligonucleotide Conjugates (AOCs): Current Status and Future Perspectives.

  2024cited by this paper
• CAR affinity modulates the sensitivity of CAR-T cells to PD-1/PD-L1-mediated inhibition

  2024cited by this paper
• Antibody-Drug Conjugate Overview: a State-of-the-art Manufacturing Process and Control Strategy

  2024cited by this paper
• T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors

  2024cited by this paper
• Exploring the next generation of antibody–drug conjugates

  2024cited by this paper
• De novo generation of SARS-CoV-2 antibody CDRH3 with a pre-trained generative large language model

  2024cited by this paper
• Highly potent and broadly neutralizing anti-CD4 trimeric nanobodies inhibit HIV-1 infection by inducing CD4 conformational alteration

  2024cited by this paper
• LNP-mRNA delivers TNF-α antibody to deep cartilage and protects against osteoarthritis

  2024cited by this paper
• Optimizing CAR-T cell therapy for solid tumors: current challenges and potential strategies

  2024cited by this paper
• Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.

  2023cited by this paper
• CAR-T Therapies in Solid Tumors: Opportunities and Challenges

  2023cited by this paper
• Monoclonal Antibody Disrupts Biofilm Structure and Restores Antibiotic Susceptibility in an Orthopedic Implant Infection Model

  2023cited by this paper
• CD19-targeted CAR T cells in refractory antisynthetase syndrome.

  2023cited by this paper
• In Vivo mRNA CAR T Cell Engineering via Targeted Ionizable Lipid Nanoparticles with Extrahepatic Tropism.

  2023cited by this paper
• The RESP AI model accelerates the identification of tight-binding antibodies

  2023cited by this paper
• The therapeutic age of the neonatal Fc receptor

  2023cited by this paper
• AB-Gen: Antibody Library Design with Generative Pre-trained Transformer and Deep Reinforcement Learning

  2023cited by this paper
• Efficient evolution of human antibodies from general protein language models

  2023cited by this paper
• Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

  2023cited by this paper
• Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies

  2023cited by this paper
• Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier

  2023cited by this paper
• Lysosomal-Cleavable Peptide Linkers in Antibody–Drug Conjugates

  2023cited by this paper
• Ozoralizumab: first Nanobody® therapeutic for rheumatoid arthritis

  2023cited by this paper
• Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2

  2023cited by this paper
• Benchmarking and integrating human B-cell receptor genomic and antibody proteomic profiling

  2023cited by this paper
• Lipid nanoparticles-loaded with toxin mRNA represents a new strategy for the treatment of solid tumors

  2023cited by this paper
• Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study

  2023cited by this paper
• Quantification of clesrovimab, an investigational, half-life extended, anti-respiratory syncytial virus protein F human monoclonal antibody in the nasal epithelial lining fluid of healthy adults.

  2023cited by this paper
• Toward real-world automated antibody design with combinatorial Bayesian optimization

  2023cited by this paper
• Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments

  2023cited by this paper
• Human monoclonal antibodies against Staphylococcus aureus A protein identified by high-throughput single-cell sequencing of phase I clinical volunteers' B cells.

  2023cited by this paper
• A lung-selective delivery of mRNA encoding broadly neutralizing antibody against SARS-CoV-2 infection

  2023cited by this paper
• A single nanobody neutralizes multiple epochally evolving human noroviruses by modulating capsid plasticity

  2023cited by this paper
• Analytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer

  2023cited by this paper
• Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection

  2023cited by this paper
• Mechanisms and research advances in mRNA antibody drug-mediated passive immunotherapy

  2023cited by this paper
• mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications

  2023cited by this paper
• Study on antibody Fc-glycosylation for optimal effector functions.

  2023cited by this paper
• Ray of dawn: Anti-PD-1 immunotherapy enhances the chimeric antigen receptor T-cell therapy in Lymphoma patients

  2023cited by this paper
• Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials

  2023cited by this paper
• In Vivo RNA Delivery to Hematopoietic Stem and Progenitor Cells via Targeted Lipid Nanoparticles

  2023cited by this paper
• Long-term outcomes following CAR T cell therapy: what we know so far

  2023cited by this paper
• Targeted tissue delivery of RNA therapeutics using antibody–oligonucleotide conjugates (AOCs)

  2023cited by this paper
• The Research Progress on Immortalization of Human B Cells

  2023cited by this paper
• Construction of Naïve and Immune Human Fab Phage Display Library.

  2023cited by this paper

• Therapeutic antibody delivery: vector tools to boost efficacy and affordability

  2026cites this paper
• Conserved Enzymatic Peptides in Bitis arietans Venom Revealed by Comparative Proteomics: Implications for Cross-Reactive Antibody Targeting

  2026cites this paper
• Antibody-Nanoparticle Conjugates for Precision Targeting of Immunosuppressive Tumor Microenvironment.

  2026cites this paper
• mRNA-Encoded Antibodies: An Emerging Paradigm in Antiviral Protection.

  2026cites this paper
• Emerging Role of Bispecific Antibodies in Precision Medicine, Cancer and Modern Therapeutics

  2026influential citation
• Synergizing Artificial Intelligence with In Vivo CAR-T Cell Generation: A New Paradigm for Democratized Immunotherapy.

  2026cites this paper
• Molecular Modeling and machine learning for predicting high-concentration antibody viscosity.

  2026cites this paper